» Authors » Ivelin S Georgiev

Ivelin S Georgiev

Explore the profile of Ivelin S Georgiev including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 105
Citations 7358
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Holt C, Janke A, Amlashi P, Jamieson P, Marinov T, Georgiev I
bioRxiv . 2025 Mar; PMID: 40060439
Computational epitope prediction remains an unmet need for therapeutic antibody development. We present three complementary approaches for predicting epitope relationships from antibody amino acid sequences. First, we analyze ~18 million...
2.
Wasdin P, Johnson N, Janke A, Held S, Marinov T, Jordaan G, et al.
bioRxiv . 2025 Mar; PMID: 40027781
The traditional process of antibody discovery is limited by inefficiency, high costs, and low success rates. Recent approaches employing artificial intelligence (AI) have been developed to optimize existing antibodies and...
3.
Jamieson P, Shen X, Abu-Shmais A, Wasdin P, Janowska K, Edwards R, et al.
bioRxiv . 2025 Feb; PMID: 39896680
HIV-1 continues to pose a significant global health challenge, requiring ongoing research into effective prevention and treatment strategies. Understanding the B cell repertoire that can be engaged upon vaccination in...
4.
Wasdin P, Abu-Shmais A, Irvin M, Vukovich M, Georgiev I
Bioinform Adv . 2024 Dec; 4(1):vbae170. PMID: 39659592
Motivation: LIBRA-seq (linking B cell receptor to antigen specificity by sequencing) provides a powerful tool for interrogating the antigen-specific B cell compartment and identifying antibodies against antigen targets of interest....
5.
Abu-Shmais A, Guo L, Khalil A, Miller R, Janke A, Vukovich M, et al.
bioRxiv . 2024 Nov; PMID: 39554078
Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are frequent drivers of morbidity and mortality in susceptible populations, most often infantile, older adults, and immunocompromised. The primary target of...
6.
Wang H, Cheng C, Dal Santo J, Shen C, Bylund T, Henry A, et al.
Cell . 2024 Oct; 187(25):7214-7231.e23. PMID: 39471811
An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection...
7.
Raju N, Kramer K, Cavallaro M, Diotti R, Shiakolas A, Campos Mota Y, et al.
J Immunol . 2024 Oct; 213(11):1605-1619. PMID: 39441352
Influenza virus is a highly contagious respiratory pathogen causing between 9.4 and 41 million infections per year in the United States in the last decade. Annual vaccination is recommended by...
8.
Johnson N, Wall S, Kramer K, Holt C, Periasamy S, Richardson S, et al.
Structure . 2024 Sep; 32(11):1893-1909.e11. PMID: 39326419
The continued emergence of deadly human coronaviruses from animal reservoirs highlights the need for pan-coronavirus interventions for effective pandemic preparedness. Here, using linking B cell receptor to antigen specificity through...
9.
Vukovich M, Shiakolas A, Lindenberger J, Richardson R, Bass L, Barr M, et al.
PLoS Pathog . 2024 Sep; 20(9):e1012499. PMID: 39292703
Broadly reactive antibodies that target sequence-diverse antigens are of interest for vaccine design and monoclonal antibody therapeutic development because they can protect against multiple strains of a virus and provide...
10.
Abu-Shmais A, Vukovich M, Wasdin P, Suresh Y, Marinov T, Rush S, et al.
mBio . 2024 Sep; 15(10):e0156024. PMID: 39264172
Throughout life, humans experience repeated exposure to viral antigens through infection and vaccination, resulting in the generation of diverse, antigen-specific antibody repertoires. A paramount feature of antibodies that enables their...